Cargando…

Safety of rilpivirine plus nucleoside reverse-transcriptase inhibitors in HIV-infected Taiwanese with a higher prevalence of hepatitis virus infection

INTRODUCTION: Combination antiretroviral therapy (cART) containing rilpivirine plus 2 NRTIs are effective antiretroviral (ARV) regimens for ARV-naive HIV-infected patients who had baseline plasma HIV RNA load (PVL) <5 log(10) copies/mL and as switch therapy for those with viral suppression. In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Pei-Ying, Cheng, Chien-Yu, Luo, Yu-Zhen, Zhang, Jun-Yu, Yang, Shan-Ping, Cheng, Shu-Hsing, Hung, Chien-Ching
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P048
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224849/ https://www.ncbi.nlm.nih.gov/pubmed/25394087 http://dx.doi.org/10.7448/IAS.17.4.19580

Ejemplares similares

Forte augmentation de la prévalence des troubles du comportement alimentaire chez les étudiants pendant la pandémie COVID-19
por: Tavolacci, M.P., et al.
Publicado: (2022)

A Rare Case Of Eosinophilic Myocarditis Due To Subacute Sars-cov-2 Illness
por: Amoateng, Richard, et al.
Publicado: (2023)

Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan
por: Wu, Pei-Ying, et al.
Publicado: (2017)

OS TELEFONES CELULARES FAZEM PARTE DA CADEIA DE TRANSMISSÃO DO SARS‐COV‐2 NO HOSPITAL?
por: Espinoz, Evelyn Patricia Sanchez, et al.
Publicado: (2021)

ÓBITOS COM CAUSAS MAL DEFINIDAS OU POUCO ESPECÍFICAS NO CONTEXTO DA PANDEMIA DE COVID-19
por: dos Santos, Daniel Félix, et al.
Publicado: (2022)

APRESENTAÇÃO DE LEISHMANIOSE VISCERAL EM PACIENTE PÓS-COVID GRAVE: UM RELATO DE CASO
por: Milagres, Ana Carolina de Almeida, et al.
Publicado: (2022)

Lipid-lowering agents for dyslipidemia in patients who were infected with HIV in Taoyuan, Taiwan
por: Cheng, Shu-Hsing, et al.
Publicado: (2014)

Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)
por: Cheng, Chien-Yu, et al.
Publicado: (2014)

Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in Taiwan: a multicenter cohort study
por: Cheng, Chien-Yu, et al.
Publicado: (2018)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Incidence of recent HCV infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan
por: Su, Yi-Ching, et al.
Publicado: (2014)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review
por: Rutherford, George W., et al.
Publicado: (2016)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study
por: Rokx, Casper, et al.
Publicado: (2014)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

Seroincidence of HIV and prevalence of transmitted drug resistance of HIV-1 strains among persons seeking voluntary counselling and testing in Taiwan
por: Liu, Wen-Chun, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus
por: Wei, Lei, et al.
Publicado: (2017)

Urinary Nucleosides as Biomarkers of Breast, Colon, Lung, and Gastric Cancer in Taiwanese
por: Hsu, Wei-Yi, et al.
Publicado: (2013)

NMR characterization of HIV-1 reverse transcriptase binding to various non-nucleoside reverse transcriptase inhibitors with different activities
por: Thammaporn, Ratsupa, et al.
Publicado: (2015)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
por: Ho, Sharlene, et al.
Publicado: (2020)

Safety, tolerability and effectiveness of HIV non-occupational prophylaxis in Taiwan
por: Li, Hsing-Chuan, et al.
Publicado: (2014)

Influence of Phosphatidylinositol-3-Kinase/Protein Kinase B-Mammalian Target of Rapamycin Signaling Pathway on the Neuropathic Pain Complicated by Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV Infection
por: Cheng, Hao, et al.
Publicado: (2018)

Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications
por: Ariën, Kevin K, et al.
Publicado: (2011)

Mitochondrial toxicities of nucleoside analogue reverse transcriptase inhibitors in AIDS cases
por: Marfatia, Yogesh S., et al.
Publicado: (2014)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
por: Famiglini, Valeria, et al.
Publicado: (2016)

Strategies in the Design and Development of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
por: Vanangamudi, Murugesan, et al.
Publicado: (2023)

Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi
por: Bello, George, et al.
Publicado: (2022)

The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
por: Galilee, Meytal, et al.
Publicado: (2018)

Fullerene Derivatives of Nucleoside HIV Reverse Transcriptase Inhibitors—In Silico Activity Prediction
por: Dąbrowska, Aleksandra, et al.
Publicado: (2018)

Nucleoside Analog Reverse-Transcriptase Inhibitors in Membrane Environment: Molecular Dynamics Simulations
por: Stachowicz-Kuśnierz, Anna, et al.
Publicado: (2023)

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors
por: Fernandes, Lívia da Rocha, et al.
Publicado: (2023)

Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
por: Balayan, Tatevik, et al.
Publicado: (2017)

CD4/CD8 ratio is not predictive of multi-morbidity prevalence in HIV-infected patients but identify patients with higher CVD risk
por: Menozzi, Marianna, et al.
Publicado: (2014)

Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen
por: Conesa-Botella, Anali, et al.
Publicado: (2010)

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe
por: Frentz, Dineke, et al.
Publicado: (2014)

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants
por: Johnson, Barry C, et al.
Publicado: (2012)

Nucleoside Analogue Reverse Transcriptase Inhibitors Differentially Inhibit Human LINE-1 Retrotransposition
por: Jones, R. Brad, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_kr9vqnu20s5edrv3n6qs712r60